TMS Co

TMS Co Tax Expense

The Income Tax Expense of TMS Co (4891.T) as of Nov 3, 2026 is 949,200.00 JPY. In the previous year, Income Tax Expense was 950,000.00 JPY — a change of -0.08% (lower).

Tax Expense

949,200.00JPY

YoY

-0.08%

Last updated:

Income Tax Expense of TMS Co is 2026 949,200.00 JPY. Income Tax Expense of TMS Co was 2025 950,000.00 JPY. It decreases by -0.08% lower compared to the previous year.

The TMS Co Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2021
950,000.00 JPY
Jan 1, 2022
2.45 M JPY
Jan 1, 2023
-545,000.00 JPY
Jan 1, 2024
950,000.00 JPY
Jan 1, 2025
950,000.00 JPY
Jan 1, 2026
949,200.00 JPY
The TMS Co Tax Expense history
YEARTax ExpenseYoY
949,200.00JPY-0.08%
950,000.00JPY0.00%
950,000.00JPY-274.31%
-545,000.00JPY-122.29%
2.45 MJPY+157.37%
950,000.00JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Income Tax Expense of TMS Co is 949,200.00 JPY in 2026.

Income Tax Expense of TMS Co changed from 950,000.00 JPY to 949,200.00 JPY, representing a -0.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense TMS Co since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TMS Co

All Key Metrics — TMS Co